HSBC has reiterated its Buy rating on Cipla, with a target price of ₹1,800 per share, implying a 26% upside from the current market price of ₹1,427.00.
The company’s Q3 PAT surpassed estimates, driven by a better sales mix, lower R&D expenses, and one-off gains. Following this performance, Cipla has raised its FY25 EBITDA margin guidance, signaling improved operational efficiency.
HSBC highlighted that the line-up of differentiated launches should bolster US sales in the medium term. The normalization of Lanreotide supply in Q1 FY26 and FDA approvals for key drugs like Abraxane and Advair are expected to act as significant catalysts for growth.
Cipla’s strong domestic portfolio, coupled with its US growth pipeline, reinforces HSBC’s positive outlook on the stock.
Disclaimer: The views and investment recommendations expressed in this article are those of the brokerage firm and do not constitute financial advice. Readers are advised to consult with a certified financial advisor before making any investment decisions. Business Upturn is not responsible for any financial losses resulting from investment actions based on this article.
